Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders
Metrics: PDF 1193 views | HTML 2679 views | ?
Shuhua Yi1, Zengjun Li1, Dehui Zou1, Wenjie Xiong1, Heng Li1, Rui Cui1,2, Chengwen Li1, Yuting Yan1, Wei Liu1, Rui Lv1, Zhen Yu1, Weiwei Chen1, Yan Xu1, Gang An1, Huijun Wang1, Kun Ru1, Tao Cheng1, Jianxiang Wang1 and Lugui Qiu1
1State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R.China
2Department of Hematology, Tianjin First Center Hospital, Tianjin, P.R.China
Lugui Qiu, email: [email protected]
Keywords: B-cell chronic lymphoproliferative disorders; chronic lymphocytic leukemia; cytogenetic aberration; del 17p; prognosis
Received: June 26, 2017 Accepted: November 17, 2017 Published: December 15, 2017
B-cell chronic lymphoproliferative disorders (B-CLPD) comprise several entities with indolent clinical manifestations but heterogeneous survival. Cytogenetic aberrations are now the standard prognostic predictors in chronic lymphocytic leukemia (CLL) but have been less investigated in other subtypes of B-CLPD. In this study, we detected cytogenetic aberrations by fluorescence in situ hybridization (FISH) in 875 B-CLPD patients, based on a panel probes locating at 13q14, 11q22, 17p13 and CEP12. We identified del17p acted as the independent adverse cytogenetic predictor for overall survival (OS) in CLL. Del13q, del11q and del17p were adverse factors for OS in Waldenström's macroglobulinemia in the univariate analysis but lost their role in the multivariate analysis. Trisomy 12 acted as an independent poor factor for both marginal zone lymphoma (MZL) and unclassified B-CLPD (BCLPD-U) subtype. Del17p did not impact survival in MZL and BCLPD-U patients. These contrasting results indicate different roles of the same cytogenetic aberrations in the pathogenesis of each B-CLPD subtype. As del17p contributed to the poorest survival in CLL and desired extraordinary treatment strategy, the imitation of CLL strategy to other B-CLPD with del17p should be carefully advocated based on this study.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.